STAY AWAY FROM THAT ERK INHIBITOR
Modified anticoagulant gets tumor cells to commit
By Anette Breindl
Friday, June 20, 2014
In findings that report counterintuitive results about both the anticoagulant heparin and the receptor tyrosine kinase ERK, scientists at Duke University have shown that by treating animals with a heparin derivative, they were able to increase the differentiation of immature cells in an animal model of neuroblastoma.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.